Phillip Capital

Analysts at global brokerage firm Phillip Capital observed that China’s market cap has shrunk to 2.5x of India’s value in 2023, compared to 4x in 2020, as sluggish economic growth erodes investor sentiment

Vedanta, Bharti, IRB, Escorts, ITC top ideas: PhillipCapital

Top 10 ideas are Vedanta, Tata Steel, Bharti Airtel, IRB Infrastructure, HCC, ITC, Zee Entertainment, Titan Company, Escorts and VA Tech Wabag, Kulkarni says.

Buy, sell, hold: 4 stocks analysts are watching

CLSA says special court verdict on former Telecom Minister Dayanidhi Maran and his brother & head of the company Kalanidhi Maran, in Aircel-Maxis case, ended long-standing legal overhang on the company. The brokerage house has upgraded the stock to buy from sell and raised target price to Rs 661 from Rs 438.

Expect 2-3 months of slowdown in two-wheelers: Phillip Capital

Decoding the auto sector‘s performance in December, Nitesh Sharma of Phillip Capital said there was a sharp hit in demand in segments where the cash component of purchases is higher. Segments such as two-wheeler and SUVs saw a higher impact, he said.

Bharti Airtel's cost structure well managed: Phillip Capital

Naveen Kulkarni of Phillip Capital spoke about Bharti Airtel numbers. Commenting on a good set of numbers, he said they the telco‘s cost structure is was managed well.

PhillipCap has buy on Britannia with price target Rs 3050

The house currently has a target price of Rs 3050 on the stock and earnings per share estimate Rs 90 for FY18, said Jubil Jain of PhillipCapital.

Buy Bharti Airtel, Idea Cellular: Naveen Kulkarni

Naveen Kulkarni, Telecom Analyst at Phillip Capital recommends buying Bharti Airtel and and Idea Cellular.

Monsoon likely to trigger tractor demand: PhillipCapital

Dhawal Doshi, Analyst - Metals, Mining and Auto, PhillipCapital, is bullish on the tractors segment. He says a good monsoon is likely to push up Escorts's stock.

Corporate bond market developing in India: Srinivasan

As of now, the Indian corporate bond market is in a development stage while regulatory changes are in the process, said Shyam Srinivasan, managing director and chief executive officer of Kerala-based The Federal Bank Ltd.

Positive on IPCA, but see 4% impact on earnings: Phillip Capital

Surya Patra, pharma analyst at Phillip Capital now estimates IPCA's institutional revenues to fall to around Rs 200 crore, from its earlier estimate of around Rs 260 crore

Sun Pharma sinks 7% on warning letter but analysts bullish

However, most analysts are still bullish on the stock and are keenly waiting to for more details in the warning letter. Few analysts have lowered target price with a cautious outlook. Phillip Capital remains positive and advises to buy on dips stating that the issue may have more sentimental impact.

Have cut Dr Reddy's target price to Rs 3250/sh: Phillip Cap

Surya Narayan Patra of Phillip Capital says that it would take minimum one year for Dr. Reddy‘s Laboratories to resolve this issue.

7800-8000 bottom to throw sharp relief rallies: Phillip Cap

India will be at the forefront when a rebound happens, says Vineet Bhatnagar of Phillip Capital. He advises staying with safe havens IT and pharma stocks.

Subscribe to Syngene; expect it to grow 20%: Phillip Cap

As per the prospectus, the company intends to sell 2.2 crore equity shares, including reservation of up to 20 lakh shares for Biocon shareholders, through an offer for sale.

Bank of Baroda valuation pick, says Vineet Bhatnagar

Vineet Bhatnagar, MD at Phillip Capital is of the view that Bank of Baroda is a valuation pick.

JSW Steel top pick, says Naveen Kulkarni

Naveen Kulkarni, co-head, research at Phillip Capital is of the view that JSW Steel is the top pick from the metal space.

Pick SBI, ICICI Bank, Axis Bank: Naveen Kulkarni

According to Naveen Kulkarni, co-head, research at Phillip Capital, one can pick ICICI Bank, Axis Bank and State Bank of India.

Aurobindo Pharma, Biocon top picks: Naveen Kulkarni

Naveen Kulkarni, co-head, research at Phillip Capital is of the view that Aurobindo Pharma and Biocon are the top picks from the pharma space.

Here's why PhillipCap cuts Tech Mah's EPS estimate, rating

Tech Mahindra missed street forecast on Tuesday with the fourth quarter consolidated profit falling 39.2 percent sequentially to Rs 472 crore, dented by lower margin and higher forex loss.

Here's what Phillip Cap recommends buying in IT space now

In an interview to CNBC-TV18, Vibhor Singhal, analyst, Phillip Capital shares his views on the IT sector and his preferred bets going ahead.

Keep BOI, PNB, SBI in portfolio: Vineet Bhatnagar

Vineet Bhatnagar - MD at Phillip Capital is of the view that one may keep Bank of India, Punjab National Bank and State Bank of India in the portfolio.

See 10-15% upside in midcap pharma space: Vineet Bhatnagar

Vineet Bhatnagar - MD at Phillip Capital expects 10-15 percent upside in midcap pharma stocks including Glenmark Pharma, Divis Laboratories, Torrent Pharma and Cadila Healthcare.

Nifty may not hit 9K in a hurry; like Glenmark: PhillipCap

Going ahead, Vineet Bhatnagar, managing director, Phillip Capital expects refinery, oil marketing companies and ONGC to show strong upward moves. He also sees another 10-15 percent upside in Glenmark, Torrent Pharma and Divis Lab.

Cross-currency impact hitting IT cos: Phillip Cap

Vibhor Singhal of Phillip Capital says cross-currency impact is hitting most IT companies post the euro depreciating 10-15 percent. Mindtree and Persistent are, however, facing client clampdowns, he adds.